nodes	percent_of_prediction	percent_of_DWPC	metapath
Bepridil—ABCB1—Mitomycin—urinary bladder cancer	0.088	0.474	CbGbCtD
Bepridil—ABCB1—Gemcitabine—urinary bladder cancer	0.0253	0.136	CbGbCtD
Bepridil—ABCB1—Cisplatin—urinary bladder cancer	0.0184	0.0991	CbGbCtD
Bepridil—ABCB1—Etoposide—urinary bladder cancer	0.0181	0.0973	CbGbCtD
Bepridil—ABCB1—Doxorubicin—urinary bladder cancer	0.0123	0.0664	CbGbCtD
Bepridil—ABCB1—Methotrexate—urinary bladder cancer	0.012	0.0643	CbGbCtD
Bepridil—CYP2D6—Doxorubicin—urinary bladder cancer	0.0116	0.0626	CbGbCtD
Bepridil—PDE1B—prostate gland—urinary bladder cancer	0.00987	0.0408	CbGeAlD
Bepridil—TNNC1—prostate gland—urinary bladder cancer	0.00947	0.0391	CbGeAlD
Bepridil—PDE1A—prostate gland—urinary bladder cancer	0.00827	0.0342	CbGeAlD
Bepridil—KCNQ1—prostate gland—urinary bladder cancer	0.00769	0.0318	CbGeAlD
Bepridil—KCNQ1—seminal vesicle—urinary bladder cancer	0.00651	0.0269	CbGeAlD
Bepridil—CACNA1H—prostate gland—urinary bladder cancer	0.00646	0.0267	CbGeAlD
Bepridil—PDE1A—smooth muscle tissue—urinary bladder cancer	0.00586	0.0242	CbGeAlD
Bepridil—PDE1A—renal system—urinary bladder cancer	0.00564	0.0233	CbGeAlD
Bepridil—CACNA1H—seminal vesicle—urinary bladder cancer	0.00546	0.0226	CbGeAlD
Bepridil—PDE1B—female reproductive system—urinary bladder cancer	0.00539	0.0223	CbGeAlD
Bepridil—CACNA1D—prostate gland—urinary bladder cancer	0.00533	0.022	CbGeAlD
Bepridil—KCNQ1—renal system—urinary bladder cancer	0.00524	0.0217	CbGeAlD
Bepridil—KCNQ1—urethra—urinary bladder cancer	0.00515	0.0213	CbGeAlD
Bepridil—CYP2D6—urine—urinary bladder cancer	0.00498	0.0206	CbGeAlD
Bepridil—CACNA1C—prostate gland—urinary bladder cancer	0.00492	0.0204	CbGeAlD
Bepridil—CACNA1H—smooth muscle tissue—urinary bladder cancer	0.00457	0.0189	CbGeAlD
Bepridil—PDE1A—female reproductive system—urinary bladder cancer	0.00452	0.0187	CbGeAlD
Bepridil—KCNQ1—female reproductive system—urinary bladder cancer	0.0042	0.0174	CbGeAlD
Bepridil—CALM3—prostate gland—urinary bladder cancer	0.00412	0.017	CbGeAlD
Bepridil—CACNA2D2—vagina—urinary bladder cancer	0.00393	0.0163	CbGeAlD
Bepridil—ATP1A1—prostate gland—urinary bladder cancer	0.00368	0.0152	CbGeAlD
Bepridil—CACNA1H—female reproductive system—urinary bladder cancer	0.00353	0.0146	CbGeAlD
Bepridil—CALM3—seminal vesicle—urinary bladder cancer	0.00349	0.0144	CbGeAlD
Bepridil—CACNA1C—smooth muscle tissue—urinary bladder cancer	0.00349	0.0144	CbGeAlD
Bepridil—CALM2—prostate gland—urinary bladder cancer	0.00324	0.0134	CbGeAlD
Bepridil—CALM1—prostate gland—urinary bladder cancer	0.00322	0.0133	CbGeAlD
Bepridil—PDE1B—lymph node—urinary bladder cancer	0.00315	0.013	CbGeAlD
Bepridil—ATP1A1—seminal vesicle—urinary bladder cancer	0.00311	0.0129	CbGeAlD
Bepridil—TNNC1—lymph node—urinary bladder cancer	0.00302	0.0125	CbGeAlD
Bepridil—KCNH2—prostate gland—urinary bladder cancer	0.00293	0.0121	CbGeAlD
Bepridil—CALM3—smooth muscle tissue—urinary bladder cancer	0.00292	0.0121	CbGeAlD
Bepridil—CALM3—urethra—urinary bladder cancer	0.00276	0.0114	CbGeAlD
Bepridil—CALM2—seminal vesicle—urinary bladder cancer	0.00274	0.0113	CbGeAlD
Bepridil—ATP1A1—epithelium—urinary bladder cancer	0.0027	0.0112	CbGeAlD
Bepridil—CACNA1C—female reproductive system—urinary bladder cancer	0.00269	0.0111	CbGeAlD
Bepridil—Benzphetamine—POR—urinary bladder cancer	0.00264	1	CrCbGaD
Bepridil—PDE1A—lymph node—urinary bladder cancer	0.00264	0.0109	CbGeAlD
Bepridil—ATP1A1—smooth muscle tissue—urinary bladder cancer	0.0026	0.0108	CbGeAlD
Bepridil—CACNA2D2—lymph node—urinary bladder cancer	0.00254	0.0105	CbGeAlD
Bepridil—ATP1A1—renal system—urinary bladder cancer	0.00251	0.0104	CbGeAlD
Bepridil—KCNH2—seminal vesicle—urinary bladder cancer	0.00248	0.0103	CbGeAlD
Bepridil—ATP1A1—urethra—urinary bladder cancer	0.00246	0.0102	CbGeAlD
Bepridil—KCNQ1—lymph node—urinary bladder cancer	0.00246	0.0102	CbGeAlD
Bepridil—CACNA1C—vagina—urinary bladder cancer	0.00243	0.01	CbGeAlD
Bepridil—CALM2—epithelium—urinary bladder cancer	0.00238	0.00984	CbGeAlD
Bepridil—CALM1—epithelium—urinary bladder cancer	0.00237	0.00979	CbGeAlD
Bepridil—CALM2—smooth muscle tissue—urinary bladder cancer	0.00229	0.00948	CbGeAlD
Bepridil—CALM1—smooth muscle tissue—urinary bladder cancer	0.00228	0.00943	CbGeAlD
Bepridil—CALM2—renal system—urinary bladder cancer	0.00221	0.00912	CbGeAlD
Bepridil—CALM1—renal system—urinary bladder cancer	0.0022	0.00908	CbGeAlD
Bepridil—CALM2—urethra—urinary bladder cancer	0.00217	0.00896	CbGeAlD
Bepridil—CALM1—urethra—urinary bladder cancer	0.00216	0.00892	CbGeAlD
Bepridil—CACNA1H—lymph node—urinary bladder cancer	0.00206	0.00853	CbGeAlD
Bepridil—CALM3—vagina—urinary bladder cancer	0.00204	0.00842	CbGeAlD
Bepridil—ATP1A1—female reproductive system—urinary bladder cancer	0.00201	0.0083	CbGeAlD
Bepridil—KCNH2—renal system—urinary bladder cancer	0.002	0.00827	CbGeAlD
Bepridil—KCNH2—urethra—urinary bladder cancer	0.00196	0.00812	CbGeAlD
Bepridil—ATP1A1—vagina—urinary bladder cancer	0.00181	0.0075	CbGeAlD
Bepridil—CALM2—female reproductive system—urinary bladder cancer	0.00177	0.00731	CbGeAlD
Bepridil—CALM1—female reproductive system—urinary bladder cancer	0.00176	0.00727	CbGeAlD
Bepridil—CACNA1D—lymph node—urinary bladder cancer	0.0017	0.00704	CbGeAlD
Bepridil—KCNH2—female reproductive system—urinary bladder cancer	0.0016	0.00662	CbGeAlD
Bepridil—CALM2—vagina—urinary bladder cancer	0.0016	0.00661	CbGeAlD
Bepridil—CALM1—vagina—urinary bladder cancer	0.00159	0.00658	CbGeAlD
Bepridil—CACNA1C—lymph node—urinary bladder cancer	0.00157	0.0065	CbGeAlD
Bepridil—KCNH2—vagina—urinary bladder cancer	0.00145	0.00599	CbGeAlD
Bepridil—CALM3—lymph node—urinary bladder cancer	0.00132	0.00544	CbGeAlD
Bepridil—ABCB1—prostate gland—urinary bladder cancer	0.00129	0.00532	CbGeAlD
Bepridil—CYP2D6—renal system—urinary bladder cancer	0.00122	0.00504	CbGeAlD
Bepridil—ATP1A1—lymph node—urinary bladder cancer	0.00117	0.00485	CbGeAlD
Bepridil—ABCB1—seminal vesicle—urinary bladder cancer	0.00109	0.0045	CbGeAlD
Bepridil—CALM2—lymph node—urinary bladder cancer	0.00103	0.00427	CbGeAlD
Bepridil—CALM1—lymph node—urinary bladder cancer	0.00103	0.00426	CbGeAlD
Bepridil—CYP2D6—female reproductive system—urinary bladder cancer	0.000976	0.00404	CbGeAlD
Bepridil—ABCB1—epithelium—urinary bladder cancer	0.000945	0.00391	CbGeAlD
Bepridil—KCNH2—lymph node—urinary bladder cancer	0.000936	0.00387	CbGeAlD
Bepridil—Hypertension—Thiotepa—urinary bladder cancer	0.000924	0.00323	CcSEcCtD
Bepridil—Arrhythmia—Gemcitabine—urinary bladder cancer	0.000924	0.00323	CcSEcCtD
Bepridil—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.000912	0.00319	CcSEcCtD
Bepridil—Myalgia—Thiotepa—urinary bladder cancer	0.000911	0.00318	CcSEcCtD
Bepridil—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000908	0.00317	CcSEcCtD
Bepridil—Anxiety—Thiotepa—urinary bladder cancer	0.000908	0.00317	CcSEcCtD
Bepridil—Tinnitus—Cisplatin—urinary bladder cancer	0.000899	0.00314	CcSEcCtD
Bepridil—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000895	0.00312	CcSEcCtD
Bepridil—ABCB1—renal system—urinary bladder cancer	0.000877	0.00363	CbGeAlD
Bepridil—ABCB1—urethra—urinary bladder cancer	0.000861	0.00356	CbGeAlD
Bepridil—Arrhythmia—Cisplatin—urinary bladder cancer	0.000861	0.00301	CcSEcCtD
Bepridil—Vision blurred—Fluorouracil—urinary bladder cancer	0.000834	0.00291	CcSEcCtD
Bepridil—Anorexia—Thiotepa—urinary bladder cancer	0.000833	0.00291	CcSEcCtD
Bepridil—Flatulence—Cisplatin—urinary bladder cancer	0.000827	0.00289	CcSEcCtD
Bepridil—Cardiac disorder—Etoposide—urinary bladder cancer	0.00082	0.00286	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000796	0.00278	CcSEcCtD
Bepridil—Vision blurred—Cisplatin—urinary bladder cancer	0.000791	0.00276	CcSEcCtD
Bepridil—Tremor—Cisplatin—urinary bladder cancer	0.000786	0.00275	CcSEcCtD
Bepridil—Cough—Gemcitabine—urinary bladder cancer	0.000786	0.00274	CcSEcCtD
Bepridil—Paraesthesia—Thiotepa—urinary bladder cancer	0.000784	0.00274	CcSEcCtD
Bepridil—Hypertension—Gemcitabine—urinary bladder cancer	0.000777	0.00271	CcSEcCtD
Bepridil—Somnolence—Thiotepa—urinary bladder cancer	0.000776	0.00271	CcSEcCtD
Bepridil—Dyspepsia—Thiotepa—urinary bladder cancer	0.000769	0.00268	CcSEcCtD
Bepridil—Myalgia—Gemcitabine—urinary bladder cancer	0.000766	0.00268	CcSEcCtD
Bepridil—Increased appetite—Epirubicin—urinary bladder cancer	0.000762	0.00266	CcSEcCtD
Bepridil—Decreased appetite—Thiotepa—urinary bladder cancer	0.000759	0.00265	CcSEcCtD
Bepridil—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000754	0.00263	CcSEcCtD
Bepridil—Myalgia—Fluorouracil—urinary bladder cancer	0.000754	0.00263	CcSEcCtD
Bepridil—Constipation—Thiotepa—urinary bladder cancer	0.000747	0.00261	CcSEcCtD
Bepridil—Pain—Thiotepa—urinary bladder cancer	0.000747	0.00261	CcSEcCtD
Bepridil—Oedema—Gemcitabine—urinary bladder cancer	0.000735	0.00257	CcSEcCtD
Bepridil—Cardiac failure—Epirubicin—urinary bladder cancer	0.000733	0.00256	CcSEcCtD
Bepridil—Oedema—Fluorouracil—urinary bladder cancer	0.000722	0.00252	CcSEcCtD
Bepridil—Myalgia—Cisplatin—urinary bladder cancer	0.000714	0.00249	CcSEcCtD
Bepridil—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000714	0.00249	CcSEcCtD
Bepridil—Anxiety—Cisplatin—urinary bladder cancer	0.000712	0.00249	CcSEcCtD
Bepridil—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00071	0.00248	CcSEcCtD
Bepridil—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000706	0.00247	CcSEcCtD
Bepridil—Increased appetite—Doxorubicin—urinary bladder cancer	0.000705	0.00246	CcSEcCtD
Bepridil—ABCB1—female reproductive system—urinary bladder cancer	0.000702	0.0029	CbGeAlD
Bepridil—Anorexia—Gemcitabine—urinary bladder cancer	0.0007	0.00245	CcSEcCtD
Bepridil—Vertigo—Etoposide—urinary bladder cancer	0.000691	0.00241	CcSEcCtD
Bepridil—Body temperature increased—Thiotepa—urinary bladder cancer	0.00069	0.00241	CcSEcCtD
Bepridil—Abdominal pain—Thiotepa—urinary bladder cancer	0.00069	0.00241	CcSEcCtD
Bepridil—Anorexia—Fluorouracil—urinary bladder cancer	0.000689	0.0024	CcSEcCtD
Bepridil—Oedema—Cisplatin—urinary bladder cancer	0.000685	0.00239	CcSEcCtD
Bepridil—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000678	0.00237	CcSEcCtD
Bepridil—Loss of consciousness—Etoposide—urinary bladder cancer	0.000676	0.00236	CcSEcCtD
Bepridil—Cough—Etoposide—urinary bladder cancer	0.000671	0.00234	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000669	0.00234	CcSEcCtD
Bepridil—Insomnia—Gemcitabine—urinary bladder cancer	0.000665	0.00232	CcSEcCtD
Bepridil—Hypertension—Etoposide—urinary bladder cancer	0.000664	0.00232	CcSEcCtD
Bepridil—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000662	0.00231	CcSEcCtD
Bepridil—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000661	0.00231	CcSEcCtD
Bepridil—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00066	0.0023	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000658	0.0023	CcSEcCtD
Bepridil—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000655	0.00229	CcSEcCtD
Bepridil—Insomnia—Fluorouracil—urinary bladder cancer	0.000653	0.00228	CcSEcCtD
Bepridil—Somnolence—Gemcitabine—urinary bladder cancer	0.000653	0.00228	CcSEcCtD
Bepridil—Anorexia—Cisplatin—urinary bladder cancer	0.000653	0.00228	CcSEcCtD
Bepridil—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000649	0.00227	CcSEcCtD
Bepridil—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000644	0.00225	CcSEcCtD
Bepridil—Somnolence—Fluorouracil—urinary bladder cancer	0.000642	0.00224	CcSEcCtD
Bepridil—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000639	0.00223	CcSEcCtD
Bepridil—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000636	0.00222	CcSEcCtD
Bepridil—ABCB1—vagina—urinary bladder cancer	0.000635	0.00263	CbGeAlD
Bepridil—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000634	0.00222	CcSEcCtD
Bepridil—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000634	0.00221	CcSEcCtD
Bepridil—Gastritis—Epirubicin—urinary bladder cancer	0.000633	0.00221	CcSEcCtD
Bepridil—Pain—Gemcitabine—urinary bladder cancer	0.000628	0.00219	CcSEcCtD
Bepridil—Constipation—Gemcitabine—urinary bladder cancer	0.000628	0.00219	CcSEcCtD
Bepridil—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000628	0.00219	CcSEcCtD
Bepridil—Asthenia—Thiotepa—urinary bladder cancer	0.000627	0.00219	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000624	0.00218	CcSEcCtD
Bepridil—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000624	0.00218	CcSEcCtD
Bepridil—Influenza—Epirubicin—urinary bladder cancer	0.000618	0.00216	CcSEcCtD
Bepridil—Pain—Fluorouracil—urinary bladder cancer	0.000618	0.00216	CcSEcCtD
Bepridil—Paraesthesia—Cisplatin—urinary bladder cancer	0.000615	0.00215	CcSEcCtD
Bepridil—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000611	0.00213	CcSEcCtD
Bepridil—Dyspnoea—Cisplatin—urinary bladder cancer	0.000611	0.00213	CcSEcCtD
Bepridil—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000609	0.00213	CcSEcCtD
Bepridil—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000607	0.00212	CcSEcCtD
Bepridil—Angina pectoris—Epirubicin—urinary bladder cancer	0.000602	0.0021	CcSEcCtD
Bepridil—Anorexia—Etoposide—urinary bladder cancer	0.000598	0.00209	CcSEcCtD
Bepridil—Diarrhoea—Thiotepa—urinary bladder cancer	0.000598	0.00209	CcSEcCtD
Bepridil—Decreased appetite—Cisplatin—urinary bladder cancer	0.000595	0.00208	CcSEcCtD
Bepridil—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000591	0.00206	CcSEcCtD
Bepridil—Drowsiness—Methotrexate—urinary bladder cancer	0.000589	0.00206	CcSEcCtD
Bepridil—Depression—Methotrexate—urinary bladder cancer	0.000588	0.00205	CcSEcCtD
Bepridil—Gastritis—Doxorubicin—urinary bladder cancer	0.000586	0.00205	CcSEcCtD
Bepridil—Pain—Cisplatin—urinary bladder cancer	0.000586	0.00204	CcSEcCtD
Bepridil—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000581	0.00203	CcSEcCtD
Bepridil—Dizziness—Thiotepa—urinary bladder cancer	0.000578	0.00202	CcSEcCtD
Bepridil—Influenza—Doxorubicin—urinary bladder cancer	0.000572	0.002	CcSEcCtD
Bepridil—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000571	0.00199	CcSEcCtD
Bepridil—Sweating—Methotrexate—urinary bladder cancer	0.000565	0.00197	CcSEcCtD
Bepridil—Paraesthesia—Etoposide—urinary bladder cancer	0.000563	0.00197	CcSEcCtD
Bepridil—Dyspnoea—Etoposide—urinary bladder cancer	0.000559	0.00195	CcSEcCtD
Bepridil—Somnolence—Etoposide—urinary bladder cancer	0.000558	0.00195	CcSEcCtD
Bepridil—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000557	0.00195	CcSEcCtD
Bepridil—Drowsiness—Epirubicin—urinary bladder cancer	0.000551	0.00193	CcSEcCtD
Bepridil—Rash—Thiotepa—urinary bladder cancer	0.000551	0.00192	CcSEcCtD
Bepridil—Dermatitis—Thiotepa—urinary bladder cancer	0.00055	0.00192	CcSEcCtD
Bepridil—Headache—Thiotepa—urinary bladder cancer	0.000547	0.00191	CcSEcCtD
Bepridil—Decreased appetite—Etoposide—urinary bladder cancer	0.000545	0.0019	CcSEcCtD
Bepridil—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000542	0.00189	CcSEcCtD
Bepridil—Body temperature increased—Cisplatin—urinary bladder cancer	0.000541	0.00189	CcSEcCtD
Bepridil—Pain—Etoposide—urinary bladder cancer	0.000537	0.00187	CcSEcCtD
Bepridil—Constipation—Etoposide—urinary bladder cancer	0.000537	0.00187	CcSEcCtD
Bepridil—Sweating—Epirubicin—urinary bladder cancer	0.000529	0.00185	CcSEcCtD
Bepridil—Asthenia—Gemcitabine—urinary bladder cancer	0.000527	0.00184	CcSEcCtD
Bepridil—Pharyngitis—Methotrexate—urinary bladder cancer	0.000525	0.00183	CcSEcCtD
Bepridil—Nausea—Thiotepa—urinary bladder cancer	0.000519	0.00181	CcSEcCtD
Bepridil—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000513	0.00179	CcSEcCtD
Bepridil—Drowsiness—Doxorubicin—urinary bladder cancer	0.00051	0.00178	CcSEcCtD
Bepridil—Bradycardia—Epirubicin—urinary bladder cancer	0.000504	0.00176	CcSEcCtD
Bepridil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000503	0.00176	CcSEcCtD
Bepridil—Rhinitis—Epirubicin—urinary bladder cancer	0.000496	0.00173	CcSEcCtD
Bepridil—Abdominal pain—Etoposide—urinary bladder cancer	0.000496	0.00173	CcSEcCtD
Bepridil—Body temperature increased—Etoposide—urinary bladder cancer	0.000496	0.00173	CcSEcCtD
Bepridil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000494	0.00173	CcSEcCtD
Bepridil—Tinnitus—Methotrexate—urinary bladder cancer	0.000493	0.00172	CcSEcCtD
Bepridil—Asthenia—Cisplatin—urinary bladder cancer	0.000491	0.00172	CcSEcCtD
Bepridil—Pharyngitis—Epirubicin—urinary bladder cancer	0.000491	0.00172	CcSEcCtD
Bepridil—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000491	0.00171	CcSEcCtD
Bepridil—Sweating—Doxorubicin—urinary bladder cancer	0.000489	0.00171	CcSEcCtD
Bepridil—Dizziness—Fluorouracil—urinary bladder cancer	0.000478	0.00167	CcSEcCtD
Bepridil—Diarrhoea—Cisplatin—urinary bladder cancer	0.000469	0.00164	CcSEcCtD
Bepridil—Bradycardia—Doxorubicin—urinary bladder cancer	0.000466	0.00163	CcSEcCtD
Bepridil—Rash—Gemcitabine—urinary bladder cancer	0.000463	0.00162	CcSEcCtD
Bepridil—Dermatitis—Gemcitabine—urinary bladder cancer	0.000463	0.00162	CcSEcCtD
Bepridil—Tinnitus—Epirubicin—urinary bladder cancer	0.000462	0.00161	CcSEcCtD
Bepridil—Headache—Gemcitabine—urinary bladder cancer	0.00046	0.00161	CcSEcCtD
Bepridil—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000459	0.0016	CcSEcCtD
Bepridil—Rhinitis—Doxorubicin—urinary bladder cancer	0.000459	0.0016	CcSEcCtD
Bepridil—Rash—Fluorouracil—urinary bladder cancer	0.000455	0.00159	CcSEcCtD
Bepridil—Dermatitis—Fluorouracil—urinary bladder cancer	0.000455	0.00159	CcSEcCtD
Bepridil—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000455	0.00159	CcSEcCtD
Bepridil—Headache—Fluorouracil—urinary bladder cancer	0.000453	0.00158	CcSEcCtD
Bepridil—Asthenia—Etoposide—urinary bladder cancer	0.00045	0.00157	CcSEcCtD
Bepridil—Arrhythmia—Epirubicin—urinary bladder cancer	0.000442	0.00154	CcSEcCtD
Bepridil—Nausea—Gemcitabine—urinary bladder cancer	0.000436	0.00152	CcSEcCtD
Bepridil—Vision blurred—Methotrexate—urinary bladder cancer	0.000434	0.00152	CcSEcCtD
Bepridil—Rash—Cisplatin—urinary bladder cancer	0.000432	0.00151	CcSEcCtD
Bepridil—Dermatitis—Cisplatin—urinary bladder cancer	0.000431	0.00151	CcSEcCtD
Bepridil—Diarrhoea—Etoposide—urinary bladder cancer	0.000429	0.0015	CcSEcCtD
Bepridil—Nausea—Fluorouracil—urinary bladder cancer	0.000429	0.0015	CcSEcCtD
Bepridil—Tinnitus—Doxorubicin—urinary bladder cancer	0.000427	0.00149	CcSEcCtD
Bepridil—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000425	0.00148	CcSEcCtD
Bepridil—Flatulence—Epirubicin—urinary bladder cancer	0.000425	0.00148	CcSEcCtD
Bepridil—Tension—Epirubicin—urinary bladder cancer	0.000423	0.00148	CcSEcCtD
Bepridil—Nervousness—Epirubicin—urinary bladder cancer	0.000419	0.00146	CcSEcCtD
Bepridil—Dizziness—Etoposide—urinary bladder cancer	0.000415	0.00145	CcSEcCtD
Bepridil—Vertigo—Methotrexate—urinary bladder cancer	0.000414	0.00144	CcSEcCtD
Bepridil—ABCB1—lymph node—urinary bladder cancer	0.000411	0.0017	CbGeAlD
Bepridil—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000409	0.00143	CcSEcCtD
Bepridil—Nausea—Cisplatin—urinary bladder cancer	0.000407	0.00142	CcSEcCtD
Bepridil—Vision blurred—Epirubicin—urinary bladder cancer	0.000406	0.00142	CcSEcCtD
Bepridil—Cough—Methotrexate—urinary bladder cancer	0.000402	0.0014	CcSEcCtD
Bepridil—Rash—Etoposide—urinary bladder cancer	0.000396	0.00138	CcSEcCtD
Bepridil—Dermatitis—Etoposide—urinary bladder cancer	0.000395	0.00138	CcSEcCtD
Bepridil—Headache—Etoposide—urinary bladder cancer	0.000393	0.00137	CcSEcCtD
Bepridil—Flatulence—Doxorubicin—urinary bladder cancer	0.000393	0.00137	CcSEcCtD
Bepridil—Myalgia—Methotrexate—urinary bladder cancer	0.000392	0.00137	CcSEcCtD
Bepridil—Tension—Doxorubicin—urinary bladder cancer	0.000391	0.00137	CcSEcCtD
Bepridil—Nervousness—Doxorubicin—urinary bladder cancer	0.000387	0.00135	CcSEcCtD
Bepridil—Vertigo—Epirubicin—urinary bladder cancer	0.000387	0.00135	CcSEcCtD
Bepridil—Syncope—Epirubicin—urinary bladder cancer	0.000386	0.00135	CcSEcCtD
Bepridil—Palpitations—Epirubicin—urinary bladder cancer	0.000381	0.00133	CcSEcCtD
Bepridil—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000379	0.00132	CcSEcCtD
Bepridil—Cough—Epirubicin—urinary bladder cancer	0.000376	0.00131	CcSEcCtD
Bepridil—Vision blurred—Doxorubicin—urinary bladder cancer	0.000376	0.00131	CcSEcCtD
Bepridil—Nausea—Etoposide—urinary bladder cancer	0.000373	0.0013	CcSEcCtD
Bepridil—Hypertension—Epirubicin—urinary bladder cancer	0.000372	0.0013	CcSEcCtD
Bepridil—Myalgia—Epirubicin—urinary bladder cancer	0.000367	0.00128	CcSEcCtD
Bepridil—Anxiety—Epirubicin—urinary bladder cancer	0.000366	0.00128	CcSEcCtD
Bepridil—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000363	0.00127	CcSEcCtD
Bepridil—Dry mouth—Epirubicin—urinary bladder cancer	0.000359	0.00125	CcSEcCtD
Bepridil—Vertigo—Doxorubicin—urinary bladder cancer	0.000358	0.00125	CcSEcCtD
Bepridil—Anorexia—Methotrexate—urinary bladder cancer	0.000358	0.00125	CcSEcCtD
Bepridil—Syncope—Doxorubicin—urinary bladder cancer	0.000358	0.00125	CcSEcCtD
Bepridil—Palpitations—Doxorubicin—urinary bladder cancer	0.000352	0.00123	CcSEcCtD
Bepridil—Oedema—Epirubicin—urinary bladder cancer	0.000352	0.00123	CcSEcCtD
Bepridil—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00035	0.00122	CcSEcCtD
Bepridil—Cough—Doxorubicin—urinary bladder cancer	0.000348	0.00121	CcSEcCtD
Bepridil—Shock—Epirubicin—urinary bladder cancer	0.000346	0.00121	CcSEcCtD
Bepridil—Hypertension—Doxorubicin—urinary bladder cancer	0.000344	0.0012	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000342	0.0012	CcSEcCtD
Bepridil—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00034	0.00119	CcSEcCtD
Bepridil—Insomnia—Methotrexate—urinary bladder cancer	0.00034	0.00119	CcSEcCtD
Bepridil—Myalgia—Doxorubicin—urinary bladder cancer	0.000339	0.00119	CcSEcCtD
Bepridil—Anxiety—Doxorubicin—urinary bladder cancer	0.000338	0.00118	CcSEcCtD
Bepridil—Paraesthesia—Methotrexate—urinary bladder cancer	0.000337	0.00118	CcSEcCtD
Bepridil—Anorexia—Epirubicin—urinary bladder cancer	0.000335	0.00117	CcSEcCtD
Bepridil—Dyspnoea—Methotrexate—urinary bladder cancer	0.000335	0.00117	CcSEcCtD
Bepridil—Somnolence—Methotrexate—urinary bladder cancer	0.000334	0.00117	CcSEcCtD
Bepridil—Dry mouth—Doxorubicin—urinary bladder cancer	0.000332	0.00116	CcSEcCtD
Bepridil—Dyspepsia—Methotrexate—urinary bladder cancer	0.000331	0.00116	CcSEcCtD
Bepridil—Decreased appetite—Methotrexate—urinary bladder cancer	0.000327	0.00114	CcSEcCtD
Bepridil—Oedema—Doxorubicin—urinary bladder cancer	0.000325	0.00114	CcSEcCtD
Bepridil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000324	0.00113	CcSEcCtD
Bepridil—Pain—Methotrexate—urinary bladder cancer	0.000321	0.00112	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00032	0.00112	CcSEcCtD
Bepridil—Shock—Doxorubicin—urinary bladder cancer	0.00032	0.00112	CcSEcCtD
Bepridil—Insomnia—Epirubicin—urinary bladder cancer	0.000318	0.00111	CcSEcCtD
Bepridil—Paraesthesia—Epirubicin—urinary bladder cancer	0.000316	0.0011	CcSEcCtD
Bepridil—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000315	0.0011	CcSEcCtD
Bepridil—Dyspnoea—Epirubicin—urinary bladder cancer	0.000314	0.00109	CcSEcCtD
Bepridil—Somnolence—Epirubicin—urinary bladder cancer	0.000313	0.00109	CcSEcCtD
Bepridil—Anorexia—Doxorubicin—urinary bladder cancer	0.00031	0.00108	CcSEcCtD
Bepridil—Dyspepsia—Epirubicin—urinary bladder cancer	0.00031	0.00108	CcSEcCtD
Bepridil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000307	0.00107	CcSEcCtD
Bepridil—Decreased appetite—Epirubicin—urinary bladder cancer	0.000306	0.00107	CcSEcCtD
Bepridil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000304	0.00106	CcSEcCtD
Bepridil—Pain—Epirubicin—urinary bladder cancer	0.000301	0.00105	CcSEcCtD
Bepridil—Constipation—Epirubicin—urinary bladder cancer	0.000301	0.00105	CcSEcCtD
Bepridil—Abdominal pain—Methotrexate—urinary bladder cancer	0.000297	0.00104	CcSEcCtD
Bepridil—Body temperature increased—Methotrexate—urinary bladder cancer	0.000297	0.00104	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000296	0.00104	CcSEcCtD
Bepridil—Insomnia—Doxorubicin—urinary bladder cancer	0.000294	0.00103	CcSEcCtD
Bepridil—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000292	0.00102	CcSEcCtD
Bepridil—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00029	0.00101	CcSEcCtD
Bepridil—Somnolence—Doxorubicin—urinary bladder cancer	0.000289	0.00101	CcSEcCtD
Bepridil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000288	0.001	CcSEcCtD
Bepridil—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000286	0.001	CcSEcCtD
Bepridil—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000283	0.000988	CcSEcCtD
Bepridil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000281	0.000981	CcSEcCtD
Bepridil—Pain—Doxorubicin—urinary bladder cancer	0.000278	0.000972	CcSEcCtD
Bepridil—Constipation—Doxorubicin—urinary bladder cancer	0.000278	0.000972	CcSEcCtD
Bepridil—Abdominal pain—Epirubicin—urinary bladder cancer	0.000278	0.000971	CcSEcCtD
Bepridil—Body temperature increased—Epirubicin—urinary bladder cancer	0.000278	0.000971	CcSEcCtD
Bepridil—Asthenia—Methotrexate—urinary bladder cancer	0.00027	0.000942	CcSEcCtD
Bepridil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000266	0.000929	CcSEcCtD
Bepridil—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000257	0.000898	CcSEcCtD
Bepridil—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000257	0.000898	CcSEcCtD
Bepridil—Diarrhoea—Methotrexate—urinary bladder cancer	0.000257	0.000898	CcSEcCtD
Bepridil—Asthenia—Epirubicin—urinary bladder cancer	0.000252	0.000881	CcSEcCtD
Bepridil—Dizziness—Methotrexate—urinary bladder cancer	0.000249	0.000868	CcSEcCtD
Bepridil—Diarrhoea—Epirubicin—urinary bladder cancer	0.000241	0.00084	CcSEcCtD
Bepridil—Rash—Methotrexate—urinary bladder cancer	0.000237	0.000827	CcSEcCtD
Bepridil—Dermatitis—Methotrexate—urinary bladder cancer	0.000237	0.000827	CcSEcCtD
Bepridil—Headache—Methotrexate—urinary bladder cancer	0.000235	0.000822	CcSEcCtD
Bepridil—Asthenia—Doxorubicin—urinary bladder cancer	0.000233	0.000815	CcSEcCtD
Bepridil—Dizziness—Epirubicin—urinary bladder cancer	0.000233	0.000812	CcSEcCtD
Bepridil—Nausea—Methotrexate—urinary bladder cancer	0.000223	0.000779	CcSEcCtD
Bepridil—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000223	0.000777	CcSEcCtD
Bepridil—Rash—Epirubicin—urinary bladder cancer	0.000222	0.000774	CcSEcCtD
Bepridil—Dermatitis—Epirubicin—urinary bladder cancer	0.000222	0.000774	CcSEcCtD
Bepridil—Headache—Epirubicin—urinary bladder cancer	0.00022	0.000769	CcSEcCtD
Bepridil—Dizziness—Doxorubicin—urinary bladder cancer	0.000215	0.000751	CcSEcCtD
Bepridil—Nausea—Epirubicin—urinary bladder cancer	0.000209	0.000729	CcSEcCtD
Bepridil—Rash—Doxorubicin—urinary bladder cancer	0.000205	0.000716	CcSEcCtD
Bepridil—Dermatitis—Doxorubicin—urinary bladder cancer	0.000205	0.000716	CcSEcCtD
Bepridil—Headache—Doxorubicin—urinary bladder cancer	0.000204	0.000712	CcSEcCtD
Bepridil—Nausea—Doxorubicin—urinary bladder cancer	0.000193	0.000675	CcSEcCtD
Bepridil—CALM1—Metabolism—NCOR1—urinary bladder cancer	2.45e-05	8.64e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—NCOR1—urinary bladder cancer	2.45e-05	8.64e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—GSTM1—urinary bladder cancer	2.45e-05	8.64e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—GSTM1—urinary bladder cancer	2.45e-05	8.64e-05	CbGpPWpGaD
Bepridil—PDE1B—Disease—HRAS—urinary bladder cancer	2.45e-05	8.63e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—FGFR3—urinary bladder cancer	2.44e-05	8.63e-05	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—SRC—urinary bladder cancer	2.43e-05	8.59e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—GPX1—urinary bladder cancer	2.42e-05	8.55e-05	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—MYC—urinary bladder cancer	2.38e-05	8.41e-05	CbGpPWpGaD
Bepridil—CALM2—Adaptive Immune System—SRC—urinary bladder cancer	2.38e-05	8.4e-05	CbGpPWpGaD
Bepridil—CALM1—Adaptive Immune System—SRC—urinary bladder cancer	2.38e-05	8.4e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—ERCC2—urinary bladder cancer	2.38e-05	8.4e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—FGFR3—urinary bladder cancer	2.36e-05	8.34e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—FGFR3—urinary bladder cancer	2.36e-05	8.34e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.36e-05	8.32e-05	CbGpPWpGaD
Bepridil—CALM3—Hemostasis—KRAS—urinary bladder cancer	2.36e-05	8.32e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—S100B—urinary bladder cancer	2.35e-05	8.31e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—GPX1—urinary bladder cancer	2.34e-05	8.27e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—GPX1—urinary bladder cancer	2.34e-05	8.27e-05	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—EGFR—urinary bladder cancer	2.33e-05	8.23e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—ERCC2—urinary bladder cancer	2.3e-05	8.12e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—ERCC2—urinary bladder cancer	2.3e-05	8.12e-05	CbGpPWpGaD
Bepridil—CALM2—Hemostasis—KRAS—urinary bladder cancer	2.28e-05	8.04e-05	CbGpPWpGaD
Bepridil—CALM1—Hemostasis—KRAS—urinary bladder cancer	2.28e-05	8.04e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—S100B—urinary bladder cancer	2.28e-05	8.03e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—S100B—urinary bladder cancer	2.28e-05	8.03e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—CREBBP—urinary bladder cancer	2.25e-05	7.95e-05	CbGpPWpGaD
Bepridil—CALM3—Innate Immune System—EGFR—urinary bladder cancer	2.25e-05	7.93e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—CDH1—urinary bladder cancer	2.24e-05	7.89e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—MTHFR—urinary bladder cancer	2.24e-05	7.89e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—RHOA—urinary bladder cancer	2.23e-05	7.87e-05	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—KRAS—urinary bladder cancer	2.2e-05	7.78e-05	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—MYC—urinary bladder cancer	2.18e-05	7.7e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—CREBBP—urinary bladder cancer	2.18e-05	7.69e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—CREBBP—urinary bladder cancer	2.18e-05	7.69e-05	CbGpPWpGaD
Bepridil—CALM1—Innate Immune System—EGFR—urinary bladder cancer	2.17e-05	7.67e-05	CbGpPWpGaD
Bepridil—CALM2—Innate Immune System—EGFR—urinary bladder cancer	2.17e-05	7.67e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—CDH1—urinary bladder cancer	2.16e-05	7.64e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—CDH1—urinary bladder cancer	2.16e-05	7.64e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—MTHFR—urinary bladder cancer	2.16e-05	7.64e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—MTHFR—urinary bladder cancer	2.16e-05	7.64e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—RHOA—urinary bladder cancer	2.16e-05	7.62e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—RHOA—urinary bladder cancer	2.16e-05	7.62e-05	CbGpPWpGaD
Bepridil—CALM3—Adaptive Immune System—EGFR—urinary bladder cancer	2.16e-05	7.61e-05	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—EGFR—urinary bladder cancer	2.13e-05	7.53e-05	CbGpPWpGaD
Bepridil—CALM3—Innate Immune System—KRAS—urinary bladder cancer	2.12e-05	7.49e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—NCOR1—urinary bladder cancer	2.12e-05	7.47e-05	CbGpPWpGaD
Bepridil—CALM3—Hemostasis—TP53—urinary bladder cancer	2.09e-05	7.39e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.09e-05	7.37e-05	CbGpPWpGaD
Bepridil—CALM2—Adaptive Immune System—EGFR—urinary bladder cancer	2.09e-05	7.36e-05	CbGpPWpGaD
Bepridil—CALM1—Adaptive Immune System—EGFR—urinary bladder cancer	2.09e-05	7.36e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—CREBBP—urinary bladder cancer	2.08e-05	7.34e-05	CbGpPWpGaD
Bepridil—CALM1—Innate Immune System—KRAS—urinary bladder cancer	2.05e-05	7.24e-05	CbGpPWpGaD
Bepridil—CALM2—Innate Immune System—KRAS—urinary bladder cancer	2.05e-05	7.24e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—NCOR1—urinary bladder cancer	2.05e-05	7.22e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—NCOR1—urinary bladder cancer	2.05e-05	7.22e-05	CbGpPWpGaD
Bepridil—CALM3—Adaptive Immune System—KRAS—urinary bladder cancer	2.04e-05	7.19e-05	CbGpPWpGaD
Bepridil—CALM1—Hemostasis—TP53—urinary bladder cancer	2.03e-05	7.15e-05	CbGpPWpGaD
Bepridil—CALM2—Hemostasis—TP53—urinary bladder cancer	2.03e-05	7.15e-05	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—KRAS—urinary bladder cancer	2.01e-05	7.11e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—CREBBP—urinary bladder cancer	2.01e-05	7.1e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—CREBBP—urinary bladder cancer	2.01e-05	7.1e-05	CbGpPWpGaD
Bepridil—CALM3—Hemostasis—HRAS—urinary bladder cancer	2e-05	7.07e-05	CbGpPWpGaD
Bepridil—CALM1—Adaptive Immune System—KRAS—urinary bladder cancer	1.97e-05	6.95e-05	CbGpPWpGaD
Bepridil—CALM2—Adaptive Immune System—KRAS—urinary bladder cancer	1.97e-05	6.95e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.97e-05	6.94e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—CXCL8—urinary bladder cancer	1.96e-05	6.91e-05	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—TP53—urinary bladder cancer	1.96e-05	6.91e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.94e-05	6.85e-05	CbGpPWpGaD
Bepridil—CALM1—Hemostasis—HRAS—urinary bladder cancer	1.94e-05	6.84e-05	CbGpPWpGaD
Bepridil—CALM2—Hemostasis—HRAS—urinary bladder cancer	1.94e-05	6.84e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.92e-05	6.77e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.92e-05	6.77e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.89e-05	6.69e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.89e-05	6.69e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—ERBB2—urinary bladder cancer	1.89e-05	6.66e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—RHOA—urinary bladder cancer	1.88e-05	6.64e-05	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—HRAS—urinary bladder cancer	1.87e-05	6.61e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—IL2—urinary bladder cancer	1.87e-05	6.61e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—TERT—urinary bladder cancer	1.86e-05	6.58e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.84e-05	6.48e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.83e-05	6.45e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—ERBB2—urinary bladder cancer	1.82e-05	6.44e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—ERBB2—urinary bladder cancer	1.82e-05	6.44e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—RHOA—urinary bladder cancer	1.82e-05	6.43e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—RHOA—urinary bladder cancer	1.82e-05	6.43e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—PPARG—urinary bladder cancer	1.81e-05	6.4e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—IL2—urinary bladder cancer	1.81e-05	6.39e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—IL2—urinary bladder cancer	1.81e-05	6.39e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.81e-05	6.38e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.81e-05	6.38e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—TERT—urinary bladder cancer	1.8e-05	6.37e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—TERT—urinary bladder cancer	1.8e-05	6.37e-05	CbGpPWpGaD
Bepridil—CALM3—Innate Immune System—HRAS—urinary bladder cancer	1.8e-05	6.36e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.8e-05	6.36e-05	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—TP53—urinary bladder cancer	1.79e-05	6.32e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—PPARG—urinary bladder cancer	1.75e-05	6.19e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—PPARG—urinary bladder cancer	1.75e-05	6.19e-05	CbGpPWpGaD
Bepridil—CALM2—Innate Immune System—HRAS—urinary bladder cancer	1.74e-05	6.16e-05	CbGpPWpGaD
Bepridil—CALM1—Innate Immune System—HRAS—urinary bladder cancer	1.74e-05	6.16e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—CREBBP—urinary bladder cancer	1.74e-05	6.15e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—ERBB2—urinary bladder cancer	1.74e-05	6.15e-05	CbGpPWpGaD
Bepridil—CALM3—Adaptive Immune System—HRAS—urinary bladder cancer	1.73e-05	6.11e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.73e-05	6.11e-05	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—HRAS—urinary bladder cancer	1.71e-05	6.04e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—FGFR3—urinary bladder cancer	1.71e-05	6.04e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—IL2—urinary bladder cancer	1.71e-05	6.04e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—PTGS2—urinary bladder cancer	1.7e-05	6.01e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.7e-05	6e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.69e-05	5.98e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—CREBBP—urinary bladder cancer	1.68e-05	5.95e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—CREBBP—urinary bladder cancer	1.68e-05	5.95e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—ERBB2—urinary bladder cancer	1.68e-05	5.95e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—ERBB2—urinary bladder cancer	1.68e-05	5.95e-05	CbGpPWpGaD
Bepridil—CALM1—Adaptive Immune System—HRAS—urinary bladder cancer	1.67e-05	5.91e-05	CbGpPWpGaD
Bepridil—CALM2—Adaptive Immune System—HRAS—urinary bladder cancer	1.67e-05	5.91e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—ESR1—urinary bladder cancer	1.66e-05	5.87e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—FGFR3—urinary bladder cancer	1.66e-05	5.84e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.66e-05	5.84e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—IL2—urinary bladder cancer	1.65e-05	5.84e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—IL2—urinary bladder cancer	1.65e-05	5.84e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—PTGS2—urinary bladder cancer	1.65e-05	5.82e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—PTGS2—urinary bladder cancer	1.65e-05	5.82e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—CDKN1A—urinary bladder cancer	1.61e-05	5.69e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—PTEN—urinary bladder cancer	1.61e-05	5.68e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—ESR1—urinary bladder cancer	1.61e-05	5.67e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—ESR1—urinary bladder cancer	1.61e-05	5.67e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.6e-05	5.64e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—CDKN1A—urinary bladder cancer	1.56e-05	5.51e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—CDKN1A—urinary bladder cancer	1.56e-05	5.51e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—PTEN—urinary bladder cancer	1.56e-05	5.49e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—PTEN—urinary bladder cancer	1.56e-05	5.49e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—EP300—urinary bladder cancer	1.53e-05	5.42e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—SRC—urinary bladder cancer	1.49e-05	5.27e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—CDKN1A—urinary bladder cancer	1.49e-05	5.26e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—PTEN—urinary bladder cancer	1.49e-05	5.24e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—EP300—urinary bladder cancer	1.48e-05	5.24e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—EP300—urinary bladder cancer	1.48e-05	5.24e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—CREBBP—urinary bladder cancer	1.46e-05	5.14e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—SRC—urinary bladder cancer	1.44e-05	5.09e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—SRC—urinary bladder cancer	1.44e-05	5.09e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—CDKN1A—urinary bladder cancer	1.44e-05	5.08e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—CDKN1A—urinary bladder cancer	1.44e-05	5.08e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—IGF1—urinary bladder cancer	1.44e-05	5.08e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—PTEN—urinary bladder cancer	1.44e-05	5.07e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—PTEN—urinary bladder cancer	1.44e-05	5.07e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—EGFR—urinary bladder cancer	1.43e-05	5.05e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—PTGS2—urinary bladder cancer	1.43e-05	5.04e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—EP300—urinary bladder cancer	1.42e-05	5e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—CREBBP—urinary bladder cancer	1.41e-05	4.97e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—CREBBP—urinary bladder cancer	1.41e-05	4.97e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—IGF1—urinary bladder cancer	1.39e-05	4.91e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—IGF1—urinary bladder cancer	1.39e-05	4.91e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—EGFR—urinary bladder cancer	1.38e-05	4.89e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—EGFR—urinary bladder cancer	1.38e-05	4.89e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—PTGS2—urinary bladder cancer	1.38e-05	4.87e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—PTGS2—urinary bladder cancer	1.38e-05	4.87e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—SRC—urinary bladder cancer	1.38e-05	4.86e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.37e-05	4.85e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—EP300—urinary bladder cancer	1.37e-05	4.84e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—EP300—urinary bladder cancer	1.37e-05	4.84e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—KRAS—urinary bladder cancer	1.35e-05	4.77e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—SRC—urinary bladder cancer	1.33e-05	4.7e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—SRC—urinary bladder cancer	1.33e-05	4.7e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.32e-05	4.66e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—RHOA—urinary bladder cancer	1.32e-05	4.65e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—KRAS—urinary bladder cancer	1.31e-05	4.62e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—KRAS—urinary bladder cancer	1.31e-05	4.62e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—EGFR—urinary bladder cancer	1.31e-05	4.62e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.29e-05	4.57e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—RHOA—urinary bladder cancer	1.27e-05	4.5e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—RHOA—urinary bladder cancer	1.27e-05	4.5e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—EGFR—urinary bladder cancer	1.26e-05	4.47e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—EGFR—urinary bladder cancer	1.26e-05	4.47e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.24e-05	4.39e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—PTEN—urinary bladder cancer	1.24e-05	4.39e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—KRAS—urinary bladder cancer	1.24e-05	4.36e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—MYC—urinary bladder cancer	1.23e-05	4.36e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—ERBB2—urinary bladder cancer	1.22e-05	4.31e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—EGFR—urinary bladder cancer	1.21e-05	4.26e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—PTEN—urinary bladder cancer	1.2e-05	4.25e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—PTEN—urinary bladder cancer	1.2e-05	4.25e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—KRAS—urinary bladder cancer	1.19e-05	4.22e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—KRAS—urinary bladder cancer	1.19e-05	4.22e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—MYC—urinary bladder cancer	1.19e-05	4.22e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—MYC—urinary bladder cancer	1.19e-05	4.22e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—EP300—urinary bladder cancer	1.19e-05	4.19e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.18e-05	4.17e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—ERBB2—urinary bladder cancer	1.18e-05	4.17e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—EGFR—urinary bladder cancer	1.17e-05	4.12e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—EGFR—urinary bladder cancer	1.17e-05	4.12e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—CXCL8—urinary bladder cancer	1.16e-05	4.08e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—HRAS—urinary bladder cancer	1.15e-05	4.06e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—EP300—urinary bladder cancer	1.15e-05	4.05e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—EP300—urinary bladder cancer	1.15e-05	4.05e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—KRAS—urinary bladder cancer	1.14e-05	4.03e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.12e-05	3.95e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—CXCL8—urinary bladder cancer	1.12e-05	3.95e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—HRAS—urinary bladder cancer	1.11e-05	3.92e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.11e-05	3.92e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—IL2—urinary bladder cancer	1.11e-05	3.9e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—KRAS—urinary bladder cancer	1.1e-05	3.89e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—KRAS—urinary bladder cancer	1.1e-05	3.89e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.08e-05	3.82e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—CCND1—urinary bladder cancer	1.08e-05	3.8e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—IL2—urinary bladder cancer	1.07e-05	3.77e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—IL2—urinary bladder cancer	1.07e-05	3.77e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—HRAS—urinary bladder cancer	1.05e-05	3.71e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—MMP9—urinary bladder cancer	1.05e-05	3.69e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.04e-05	3.68e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—CCND1—urinary bladder cancer	1.04e-05	3.68e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—CCND1—urinary bladder cancer	1.04e-05	3.68e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—PTEN—urinary bladder cancer	1.04e-05	3.67e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.02e-05	3.6e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—HRAS—urinary bladder cancer	1.02e-05	3.59e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—HRAS—urinary bladder cancer	1.02e-05	3.59e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—MMP9—urinary bladder cancer	1.01e-05	3.57e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—MMP9—urinary bladder cancer	1.01e-05	3.57e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.01e-05	3.56e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.01e-05	3.56e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—PTEN—urinary bladder cancer	1.01e-05	3.55e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—PTEN—urinary bladder cancer	1.01e-05	3.55e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—EP300—urinary bladder cancer	9.92e-06	3.5e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—HRAS—urinary bladder cancer	9.69e-06	3.42e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—SRC—urinary bladder cancer	9.65e-06	3.41e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—EP300—urinary bladder cancer	9.6e-06	3.39e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—EP300—urinary bladder cancer	9.6e-06	3.39e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—PTEN—urinary bladder cancer	9.43e-06	3.33e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—HRAS—urinary bladder cancer	9.38e-06	3.31e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—HRAS—urinary bladder cancer	9.38e-06	3.31e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—SRC—urinary bladder cancer	9.33e-06	3.29e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—SRC—urinary bladder cancer	9.33e-06	3.29e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—EP300—urinary bladder cancer	8.99e-06	3.17e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—PTEN—urinary bladder cancer	8.88e-06	3.14e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—MYC—urinary bladder cancer	8.64e-06	3.05e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—EP300—urinary bladder cancer	8.47e-06	2.99e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—EGFR—urinary bladder cancer	8.45e-06	2.98e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—MYC—urinary bladder cancer	8.36e-06	2.95e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—MYC—urinary bladder cancer	8.36e-06	2.95e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—EGFR—urinary bladder cancer	8.18e-06	2.89e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—EGFR—urinary bladder cancer	8.18e-06	2.89e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—KRAS—urinary bladder cancer	7.99e-06	2.82e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—KRAS—urinary bladder cancer	7.73e-06	2.73e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—KRAS—urinary bladder cancer	7.73e-06	2.73e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—TP53—urinary bladder cancer	7.1e-06	2.51e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—TP53—urinary bladder cancer	6.87e-06	2.42e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—TP53—urinary bladder cancer	6.87e-06	2.42e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—HRAS—urinary bladder cancer	6.79e-06	2.4e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—HRAS—urinary bladder cancer	6.57e-06	2.32e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—HRAS—urinary bladder cancer	6.57e-06	2.32e-05	CbGpPWpGaD
